<p>Pertuzumab is a HER2/neu receptor antagonist indicated for:<br />
<br />
Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.<br />
<br />
Use in combination with trastuzumab and chemotherapy as:</p>

<ul>
	<li>Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.</li>
	<li>Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence</li>
</ul>